Cue Biopharma (CUE) Insider Vincent Sells $32K of Stock

On October 12, 2026, Michael Vincent Meluzio, the VP and Principal Accounting Officer of Cue Biopharma, Inc. (CUE), sold 1,144 shares at $28.05 each. This sale amounted to about $32,089. The transaction was not planned and was reported through a Form 4 filing with the SEC.

Insider Buying and Selling at Cue Biopharma, Inc.

On the same day as Meluzio's sale, several other insiders also sold shares. CEO Lin Shao-Lee sold 11,087 shares at an average price of $27.55, totaling approximately $305,490. Additionally, Chief Legal Compliance Officer Ray Sumita sold 1,844 shares at the same price of $28.05, which was valued at about $51,724. Sumita J.D. Ray also sold 1,844 shares for a similar amount.

Other Institutional Activity in Cue Biopharma

Several institutional investors have been active in Cue Biopharma recently. Bleichroeder LP increased its holdings by 143,381 shares, bringing its total to 370,682 shares worth about $6.19 million. Driehaus Capital Management, LLC added 146,072 shares, totaling 292,144 shares valued at approximately $4.88 million. Vanguard Capital Management LLC grew its stake by 79,785 shares, ending with 161,700 shares worth about $2.70 million. Ikarian Capital, LLC and Tetragon Partners GP Ltd. also added to their positions, with increases of 52,182 shares and 46,910 shares, respectively.

Cue Biopharma, Inc. Stock Down 3.7%

As of October 16, 2026, Cue Biopharma is trading around $17.98, which is significantly below its 50-day moving average of $27.56. The stock is also below its 200-day average and well off its 52-week high of $45.50, reflecting a challenging environment for the company. The shares are above their 52-week low of $4.98, indicating some resilience in the stock price.

Recent Earnings

Cue Biopharma reported trailing twelve-month revenue of approximately $37.66 million, but it has not recorded positive earnings, leading to a negative P/E ratio. The company is in a phase of growth, focusing on developing therapies for immunological disorders, with its lead asset, CUE-221, currently in Phase 2 development.

Insider Buying and Selling at Cue Biopharma, Inc.

On October 12, 2026, multiple insiders sold shares of Cue Biopharma. CEO Lin Shao-Lee sold 11,087 shares for approximately $305,490. Ray Sumita, the Chief Legal Compliance Officer, sold 1,844 shares valued at about $51,724. Sumita J.D. Ray also sold 1,844 shares on the same day, which totaled around $51,724.

Analysts Set New Price Targets

On September 18, 2026, B. Riley Securities initiated coverage on Cue Biopharma, giving it a Buy rating and setting a price target of $83.00. The current analyst consensus suggests a mean price target of $88.00 based on three opinions, indicating potential for significant upside from current levels.

About Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage therapeutics company based in Boston, MA. It focuses on creating treatments for immunological disorders. Its lead product, CUE-221, is in development for allergic diseases, utilizing the Immuno-STAT platform to target disease-specific T cells without affecting the overall immune system.

Bottom Line

Investors should monitor Cue Biopharma closely, especially with upcoming earnings expected in November 2026 and ongoing developments in its drug pipeline. The recent insider selling reflects a broader trend among executives but does not necessarily indicate a lack of confidence in the company's future prospects.